LifeVantage Corporation (FRA:L2T1)

Market Cap	72.60M
Revenue (ttm)	195.07M
Net Income (ttm)	8.64M
Shares Out	n/a
EPS (ttm)	0.66
PE Ratio	8.41
Forward PE	5.90
Dividend	0.16 (2.86%)
Ex-Dividend Date	Dec 1, 2025

Volume	n/a
Average Volume	218
Open	5.65
Previous Close	5.60
Day's Range	5.65 - 5.65
52-Week Range	5.25 - 25.00
Beta	n/a
RSI	40.57
Earnings Date	Feb 3, 2026

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre- and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fati...

• Industry: Pharmaceutical Preparations
• CEO: Steven Fife
• Employees: 238
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: L2T1

Financial Performance

In 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Financial numbers in USD